Evidence map›Paper›PMID 36330076›Full record

ArticleBioactive materials2022

Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology.

Bibin Anand, Qi Wu, Maryam Nakhaei-Nejad, Govindarajan Karthivashan, Lyudmyla Dorosh, Sara Amidian, Abhishek Dahal, Xiuju Li, Maria Stepanova, Holger Wille and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Native PLGA nanoparticles attenuate disease pathology via multiple pathways in 5xFAD Alzheimer's model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bibin AnandDepartment of Medicine (Neurology), University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Qi WuDepartment of Medicine (Neurology), University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Maryam Nakhaei-NejadDepartment of Medicine (Neurology), University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Govindarajan KarthivashanDepartment of Medicine (Neurology), University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Lyudmyla DoroshDepartment of Electrical and Computer Engineering, University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Sara AmidianCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Abhishek DahalCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Xiuju LiDepartment of Medicine (Neurology), University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Maria StepanovaDepartment of Electrical and Computer Engineering, University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Holger WilleCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Fabrizio GiulianiDepartment of Medicine (Neurology), University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.
Satyabrata KarDepartment of Medicine (Neurology), University of Alberta, Edmonton, Alberta, T6G 2M8, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is believed to be triggered by increased levels/aggregation of β-amyloid (Aβ) peptides. At present, there is no effective disease-modifying treatment for AD. Here, we evaluated the therapeutic potential of FDA-approved native poly(d,l-lactide-

Indexed as

Alzheimer's diseaseNanoparticlesNeuroprotectionPeptide aggregationβ-amyloid

Identifiers

PMID36330076
PMCPMC9614411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.